Archiv
Archiv anzeigen:
bis


Eltrombopag for Aplastic Anemia

David Green, MD, PhD reviewing Townsley DM et al. N Engl J Med 2017 Apr 20

Combining eltrombopag with antithymocyte globulin and cyclosporine improved complete response rate and overall survival.


Is Contralateral Prophylactic Mastectomy for Me?

Laila Samiian, MD reviewing Jagsi R et al. JAMA Surg 2017 Mar 1

The surgeon's recommendation for or against CPM can significantly influence a woman's decision about the surgery.


Radiotherapy for Breast Cancer: Long-Term Consequences

William J. Gradishar, MD reviewing Taylor C et al. J Clin Oncol 2017 Mar 20, Shaitelman SF et al. J Clin Oncol 2017 Mar 20

The benefits far outweigh the risks for most patients, thanks largely to efforts to reduce smoking and to expose less normal tissue to RT.


An Anti–Trop-2 Antibody–Drug Conjugate for Triple-Negative Breast Cancer

William J. Gradishar, MD reviewing Bardia A et al. J Clin Oncol 2017 Mar 14

Sacituzumab govitecan produced durable responses in heavily pretreated patients and had a manageable safety profile.


Adjuvant Bisphosphonates for Patients with Breast Cancer

William J. Gradishar, MD reviewing Dhesy-Thind S et al. J Clin Oncol 2017 Mar 6

The use of bisphosphonates as adjuvant therapy can be considered for postmenopausal women with breast cancer who are candidates for systemic therapy.


Initial Treatment with Transplantation for Patients with Multiple Myeloma

Michael E. Williams, MD, ScM reviewing Attal M et al. N Engl J Med 2017 Apr 7

Consolidation with autologous stem-cell transplantation significantly improved progression-free survival versus triplet induction therapy alone.


Reducing Fatal Hemorrhage in Acute Promyelocytic Leukemia

David Green, MD, PhD reviewing Mantha S et al. Blood 2017 Mar 30, Cao M et al. Blood 2017 Mar 30

Eliminating extracellular chromatin, released by disintegrating blasts, might lower the incidence of hemorrhagic deaths.


Outpatient Palliative Care for Advanced Cancer Patients: Another Randomized Trial

Allan S. Brett, MD reviewing Temel JS et al. J Clin Oncol 2017 Mar 10

A palliative care intervention appeared to benefit patients with lung cancer but not patients with certain gastrointestinal cancers.


New Approach to Protecting Ovarian Reserve During Chemotherapy

Anthony L. Komaroff, MD reviewing Kano M et al. Proc Natl Acad Sci U S A 2017 Feb 28, Woodruff TK. Proc Natl Acad Sci U S A 2017 Feb 28

Müllerian inhibiting substance is being explored as a reversible protective agent.


Antenatal Management of Fetal Alloimmune Thrombocytopenia

David Green, MD, PhD reviewing Winkelhorst D et al. Blood 2017 Mar 16

Intravenous gamma globulin is recommended at 12 to 20 weeks of gestation for pregnant women with history of neonatal intracranial bleeding.


Archiv
Seite von 53
Editorial Member Board Empfehlungen

Prof. Dr. med. Florian Otto

Tumor- und Brustzentrum ZeTuP, St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.

Kommentar weiterlesen

Management of Localized Prostate Cancer: Data at Last

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hamdy FC et al. N Engl J Med 2016 Sep 14, D'Amico AV. N Engl J Med 2016 Sep 14

Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.


Hereditary Thrombophilia and Risk for Pregnancy-Associated Venous Thromboembolism

David Green, MD, PhD reviewing Gerhardt A et al. Blood 2016 Sep 9

Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.


Little Benefit to Extensive Breast Cancer Monitoring

William J. Gradishar, MD reviewing Accordino MK et al. J Clin Oncol 2016 Aug 20, Smith KL and Smith TJ. J Clin Oncol 2016 Aug 20

The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.


FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer

David H. Ilson, MD, PhD reviewing Enzinger PC et al. J Clin Oncol 2016 Aug 10

Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.


Reversing Anticoagulant-Associated Bleeding with Andexanet

David Green, MD, PhD reviewing Connolly SJ et al. N Engl J Med 2016 Aug 30

Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.


Another Tool to Help Breast Cancer Patients Avoid Chemotherapy

William J. Gradishar, MD reviewing Cardoso F et al. N Engl J Med 2016 Aug 25, Hudis CA and Dickler M. N Engl J Med 2016 Aug 25

A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.


Daratumumab for Advanced Light Chain Amyloidosis

David Green, MD, PhD reviewing Sher T et al. Blood 2016 Aug 19

Declines in light chain levels were achieved in heavily pretreated patients.


HER2 a Potential Target in Colorectal Cancer

David H. Ilson, MD, PhD reviewing Sartore-Bianchi A et al. Lancet Oncol 2016 Jun

The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.


Resistance to Anti–PD-1 Therapy in Melanoma Patients

Jeffrey A. Sosman, MD reviewing Zaretsky JM et al. N Engl J Med 2016 Jul 13

Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.


Adjuvant S-1 for Resected Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Uesaka K et al. Lancet 2016 Jun 2, Ko AH et al. Lancet 2016 Jun 2

Overall survival was significantly better with S-1 versus gemcitabine.